Acute HIV Infection Clinical Trial
To describe clinical, immunological, and virological characteristics of persons with acute HIV infection 1. To describe demographics and behavioral risk factors for those identified with acute HIV infection 2. To describe neurocognitive function and neuroimaging findings in acute HIV infection as well as describe immune response, HIV-1 genotypes and sequences in the cerebrospinal fluid. 3. To describe the number and characteristics of sexual contacts 4. To describe the willingness of acute HIV-infected subjects to allow the tracking of their sexual contacts for voluntary HIV counseling and testing (VCT) 5. To describe immune response, HIV-1 genotypes and sequences in the genital compartment 6. To describe T cell depletion in the gut mucosa in acute HIV infection and describe the changes in gut T cell during follow up 7. To archive samples for future investigations including determination of viral evolution, and cell-mediated and humoral immune responses in peripheral blood and mucosal compartments
This study will establish an acute infection cohort which is predominantly non-subtype B. Description of the early events in HIV infection is critical to HIV vaccine development and understanding HIV-1 immunopathogenesis. The ability to establish this cohort and identify individuals with acute HIV-1 infection would provide the basis for future hypothesis-driven proposals. Subjects will be recruited at the TRCARC. Subjects seeking VCT will be asked to provide contact information. Blood samples, either plasma or whole blood collected on filter paper (dried blood spots, or DBS) will be screened for acute HIV infection by pooled or individual NAT if non-reactive after screening by an EIA capable of detecting both HIV antibody and antigen (4th generation or sensitive EIA). Additionally, 4th generation reactive samples will be screened with a non-IgM sensitive EIA capable of detecting HIV antibody only (less sensitive EIA) within 1-2 days of sample collection. Those who are found to have acute HIV infection will be asked to enroll in the cohort study. These acute HIV-infected participants will be followed prospectively at week 0, day 2, 3, 5, 7, 10 then weeks 2, 4, 8, 12, 16, 20, 24, then every 12 weeks until the end of the study (maximum of 192 weeks of follow up). Subjects will receive blood testing for CD4, HIV RNA, ALT, creatinine and lipids, and urinalysis. Subjects will be asked to complete a questionnaire on HIV risk behavior. Archiving of plasma and PBMC for future immunologic and virologic testing will be performed. Optional study procedures include 1) collection of genital secretions 2) collection of cerebrospinal fluid 3) brain MRI/MRS without gadolinium 4) sampling of gut-associated lymphoid tissue by colon biopsy 5) genetic testing 6) tracking of and offering VCT to sexual contacts of acute HIV-infected subjects. Subjects are encouraged to be hospitalized for the first 3-7 days for post-procedural observation and for ease of follow up. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02384395 -
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
|
N/A | |
Completed |
NCT00734344 -
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
|
N/A | |
Completed |
NCT01434706 -
Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection
|
N/A | |
Active, not recruiting |
NCT03711253 -
Empiric Treatment for Acute HIV in the ED
|
Phase 4 | |
Completed |
NCT01154673 -
Intense Acute Infection Study
|
Phase 2/Phase 3 | |
Terminated |
NCT00855413 -
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine
|
Phase 4 | |
Completed |
NCT02467439 -
Acute Partner and Social Contact Referral: iKnow
|
N/A | |
Not yet recruiting |
NCT05719441 -
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
|
Phase 2 | |
Completed |
NCT03579381 -
Specimen Repository for HIV Immunopathogenesis
|
||
Completed |
NCT01369056 -
HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence
|
N/A | |
Completed |
NCT02170246 -
Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection
|
Phase 1 | |
Completed |
NCT02470351 -
Assessment of the HIV CNS Reservoir, Neurological and Neuro-cognitive Effects, and Source of Rebound HIV in CNS
|
N/A | |
Completed |
NCT02750059 -
Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis
|
Phase 2 | |
Completed |
NCT02475915 -
Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection
|
Phase 1/Phase 2 | |
Completed |
NCT00924898 -
Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
|
Phase 4 | |
Completed |
NCT02614950 -
Viral Suppression After Analytic Treatment Interruption in Thai Patients Who Initiated Highly Active Antiretroviral Therapy During Acute HIV Infection
|
N/A | |
Completed |
NCT01197027 -
Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection
|
Phase 3 | |
Active, not recruiting |
NCT02231281 -
Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults
|
Phase 3 | |
Recruiting |
NCT05728996 -
Netherlands Cohort Study on Acute HIV Infection
|
||
Recruiting |
NCT00796263 -
Antiretroviral Therapy for Acute and Chronic HIV Infection
|
Phase 3 |